[go: up one dir, main page]

Kayser et al., 1990 - Google Patents

Binding of neuroendocrine markers and biotinylated sex hormones and the survival in human lung cancer

Kayser et al., 1990

Document ID
8081707108956111719
Author
Kayser K
Gabius H
Köhler A
Runtsch T
Publication year
Publication venue
Lung Cancer

External Links

Snippet

The specificity and the sensitivity of neuroendocrine markers to distinguish small cell anaplastic carcinoma (SCCL) from non-small cell carcinoma of lung (NSCCL) was evaluated in two different sets of patients comprising 142 cases and 80 cases, respectively …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Similar Documents

Publication Publication Date Title
Volante et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy
EP0782709B1 (en) Detection of cancer
Kurokawa et al. Expression of GLUT‐1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F‐18]‐fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary
Raymond et al. Vimentin—a new prognostic parameter in breast carcinoma?
US5698402A (en) Methods for diagnosing benign prostatic hyperplasia
Ofuji et al. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
Lin et al. Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma
Tsujikawa et al. Functional oestrogen receptor α imaging in endometrial carcinoma using 16α-[18F] fluoro-17β-oestradiol PET
US20080305558A1 (en) Cancer Screening Test
US8133737B2 (en) Systems and methods for breast cancer detection and risk assessment
Karat et al. Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study
Basolo et al. Expression of the Mr 67,000 laminin receptor is an adverse prognostic indicator in human thyroid cancer: an immunohistochemical study.
Magnani et al. Diagnosis of persistent ovarian carcinoma with three-step immunoscintigraphy
Tatsuta et al. Value of serum alpha-fetoprotein and ferritin in the diagnosis of hepatocellular carcinoma
Kayser et al. Binding of neuroendocrine markers and biotinylated sex hormones and the survival in human lung cancer
Baron et al. A preliminary study of serum concentrations of soluble epidermal growth factor receptor (sErbB1), gonadotropins, and steroid hormones in healthy men and women
Ding et al. Fulvestrant may falsely increase 17β-estradiol levels in immunoassays: a case report of a 57-year-old postmenopausal patient with recurrent estrogen receptor-positive breast cancer
EP0040058B1 (en) Method for detection of oncofetal antigen, for detection of cancer, for evaluation for cancer therapy and diagnostic kit suitable for such purpose
Truong et al. VPAC1-targeted PET/CT scan: improved molecular imaging for the diagnosis of prostate cancer using a novel cell surface antigen
Murad et al. Standardized classification schemes in reporting oncologic PET/CT
Ward et al. Circulating tumour‐associated antigen detected by the monoclonal antibody HMFG2 in human epithelial ovarian cancer
Sawabu et al. Serum tumor markers in patients with hepatocellular carcinoma: Diagnosis of α-fetoprotein-low or-negative patients
Montalto et al. Clinical evaluation of pancreatitis-associated protein as a serum marker of hepatocellular carcinoma: comparison with α-fetoprotein
Tsou et al. Evaluation of 5′‐nucleotide phosphodiesterase isozyme‐V as a predictor for liver metastasis in breast cancer patients
Traish et al. Estrogen receptor functional status in human breast cancer